Alpa Laboratories Limited (ALPA) AI Stock Analysis

• Market Cap: ₹1.83B
• Dividend Yield: N/A
• Average Volume (3M): 2.10K
• Price to Earnings (P/E): 7.0
• Beta (1Y): 1.25
• Revenue Growth: 5.12%
• EPS Growth: 38.44%
• Country: IN
• Employees: 410
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 5.59
• Shares Outstanding: 21,040,600
• 10 Day Avg. Volume: 2,303
• 30 Day Avg. Volume: 2,105
• PEG Ratio: 0.73
• Price to Book (P/B): 1.31
• Price to Sales (P/S): 2.00
• P/FCF Ratio: -104.73
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹95.00
• Price Target Upside: 7.78% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 64 Neutral
• Price Target: ₹95.00 ▲(7.78% Upside)

Alpa Laboratories Limited's stock score is primarily influenced by its strong financial performance and attractive valuation, suggesting potential undervaluation. However, technical analysis indicates bearish momentum, which could pose short-term risks. The absence of earnings call insights and corporate events leaves these areas unaddressed.

Alpa Laboratories Limited Business Overview & Revenue Model

Company Description

Alpa Laboratories Limited (ALPA) is a prominent player in the pharmaceutical and biotechnology sectors, specializing in the development, manufacturing, and marketing of a wide range of pharmaceutical products and active pharmaceutical ingredients (APIs). The company is dedicated to enhancing health and well-being through innovative solutions, focusing on therapeutic areas such as cardiology, oncology, and infectious diseases. ALPA's core offerings include finished dosage forms, injectables, and high-quality APIs, catering to both domestic and international markets.

How the Company Makes Money

Alpa Laboratories Limited generates revenue primarily through the sale of its pharmaceutical products and active pharmaceutical ingredients. The company's revenue model relies on a diversified portfolio that includes both prescription medications and over-the-counter products, allowing it to capture a wide range of customer needs. Key revenue streams include direct sales to healthcare providers, hospitals, and pharmacies, as well as partnerships with other pharmaceutical companies for the development and distribution of specialty medications. Additionally, ALPA may benefit from licensing agreements and collaborations with research institutions that enhance its product offerings and market reach. Ongoing investments in research and development also contribute to the company's ability to innovate and introduce new products, further driving its revenue growth.

Alpa Laboratories Limited Financial Statement Overview

Summary

Alpa Laboratories Limited demonstrates strong revenue growth and profitability, supported by a robust balance sheet with minimal leverage. However, cash flow challenges, particularly negative free cash flow, could pose risks if not addressed. The company should focus on improving cash conversion to sustain its growth trajectory.

Income Statement

Alpa Laboratories Limited shows a strong revenue growth rate of 16.97% in the latest year, indicating robust demand for its products. The company maintains healthy profit margins, with a net profit margin of 17.34% and an EBIT margin of 23.03%, reflecting efficient cost management. However, the gross profit margin has decreased compared to previous years, suggesting potential pressure on production costs or pricing strategies.

Balance Sheet

The company's balance sheet is solid, with a very low debt-to-equity ratio of 0.0002, indicating minimal leverage and financial risk. Return on equity is strong at 11.38%, showcasing effective use of shareholder funds to generate profits. The equity ratio of 77.03% highlights a stable financial structure with a significant portion of assets financed by equity.

Cash Flow

Cash flow analysis reveals challenges, with negative free cash flow and a declining free cash flow growth rate. The operating cash flow to net income ratio is 0.20, suggesting that not all earnings are being converted into cash. The negative free cash flow to net income ratio indicates potential issues in cash generation relative to reported profits.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.10B	1.12B	1.09B	924.10M	1.11B	964.13M
Gross Profit	310.84M	193.99M	188.90M	307.44M	344.08M	316.58M
EBITDA	348.15M	281.01M	229.96M	174.43M	214.31M	130.29M
Net Income	262.32M	195.03M	167.76M	125.83M	140.92M	72.47M
Balance Sheet
Total Assets	0.00	2.23B	1.82B	1.67B	1.55B	1.40B
Cash, Cash Equivalents and Short-Term Investments	1.13B	1.13B	928.54M	808.42M	702.74M	424.92M
Total Debt	0.00	343.00K	52.47M	23.04M	58.47M	1.92M
Total Liabilities	-1.71B	511.59M	304.62M	326.92M	335.08M	327.27M
Stockholders Equity	1.71B	1.71B	1.52B	1.35B	1.22B	1.08B
Cash Flow
Free Cash Flow	0.00	-21.42M	-27.36M	77.78M	77.49M	-49.20M
Operating Cash Flow	0.00	92.37M	36.49M	89.04M	99.40M	-17.00M
Investing Cash Flow	0.00	-35.13M	-133.36M	21.27M	-156.10M	58.60M
Financing Cash Flow	0.00	-52.47M	25.83M	-37.93M	54.42M	1.90M

Alpa Laboratories Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 88.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ALPA, the sentiment is Negative. The current price of 88.14 is below the 20-day moving average (MA) of 90.64, below the 50-day MA of 93.83, and below the 200-day MA of 104.44, indicating a bearish trend. The MACD of -1.60 indicates Negative momentum. The RSI at 36.29 is Neutral, neither overbought nor oversold. The STOCH value of 30.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ALPA.

Alpa Laboratories Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BAFNAPH	65 Neutral	₹3.66B	44.26	―	―	2.36%	2924.94%
ALPA	64 Neutral	₹1.83B	6.98	―	―	5.12%	38.44%
AAREYDRUGS	60 Neutral	₹2.53B	60.50	―	―	-4.74%	-35.14%
BALPHARMA	60 Neutral	₹1.29B	15.11	―	1.49%	-14.16%	10.85%
VAISHALI	55 Neutral	₹1.10B	335.29	―	―	15.13%	-51.89%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
KREBSBIO	41 Neutral	₹1.48B	―	―	―	-31.91%	-38.46%